PAGE YIN: Open Payments
NPI 1174978126 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 35 payments from 11 companies in 2025. Trend: 2023 $729 · 2024 $670 · 2025 $1,352
Food & beverage: $1,226Education: $126
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $291 |
| Axsome Therapeutics, Inc. | 2 | $250 |
| E.R. Squibb & Sons, L.L.C. | 10 | $201 |
| Alkermes, Inc. | 3 | $160 |
| Madrigal Pharmaceuticals | 1 | $130 |
| ABBVIE INC. | 5 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Lundbeck LLC | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
Products named: Auvelity, COBENFY, UZEDY, LYBALVI, REZDIFFRA, VRAYLAR, REXULTI, CAPLYTA.
Industry payments across NY — which companies pay providers there.
